Literature DB >> 15476223

Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group.

Nathalie Costedoat-Chalumeau1, Zahir Amoura, Jean-Marc Lupoglazoff, Du Le Thi Huong, Isabelle Denjoy, Danièle Vauthier, Djamel Sebbouh, Olivier Fain, Sophie Georgin-Lavialle, Pascale Ghillani, Lucile Musset, Bertrand Wechsler, Pierre Duhaut, Jean-Charles Piette.   

Abstract

OBJECTIVE: Aside from congenital heart block (CHB), sinus bradycardia and prolongation of the corrected QT (QTc) interval have been reported in infants born to mothers with anti-SSA antibodies. To assess the pathologic nature of these manifestations, this study focused on electrocardiographic (EKG) variations in these children, comparing them with findings in a control group.
METHODS: We studied 165 consecutive pregnancies in 106 anti-SSA-positive women with connective tissue diseases (CTDs). EKGs obtained on 58 children of this group were compared with those obtained on 85 infants born to mothers with CTD who were negative for both anti-SSA and anti-SSB.
RESULTS: No statistically significant difference was seen between the 2 study groups with regard to gestational age, prematurity, birth weight, age of the children at the time of EKG, age of the mothers, or treatments received by the mothers during their pregnancies. Seven of 137 children developed cutaneous neonatal lupus syndrome; 1 child developed CHB (CHB risk of 1 in 99 [1%] if only the first prospectively observed pregnancy in women without a history of CHB is included in the analysis). For EKGs recorded during the first 2 months of life, the mean +/- SD PR interval was 96 +/- 16 msec in the anti-SSA-positive group and 96 +/- 13 msec in the anti-SSA-negative group (P = 0.84), with mean QTc values of 397 +/- 27 and 395 +/- 25 msec (P = 0.57) and mean heart rates of 141 +/- 23 and 137 +/- 21 beats per minute (P = 0.20), respectively. No difference in the PR interval, QTc interval, or heart rate was observed for EKGs obtained between 2 and 4 months of life. When EKGs obtained at 0-2 months were compared with those obtained at 2-4 months, a physiologic prolongation of the QTc interval was observed in both study groups. No sudden infant death or symptomatic arrhythmia occurred during the first year of life.
CONCLUSION: The EKG findings in children of anti-SSA-positive and anti-SSA-negative mothers were not significantly different. Our results suggest that the prolongation of the QTc interval and sinus bradycardia that have recently been reported in children of mothers with anti-SSA antibodies occur independently of the anti-SSA antibodies. The pathologic nature of these EKG variations was not confirmed by our controlled study. Copyright 2004 American College of Rheumatology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476223     DOI: 10.1002/art.20554

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

1.  Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus.

Authors:  Peter M Izmirly; Amit Saxena; Mimi Y Kim; Dan Wang; Sara K Sahl; Carolina Llanos; Deborah Friedman; Jill P Buyon
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

2.  Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.

Authors:  Peter M Izmirly; Nathalie Costedoat-Chalumeau; Cecilia N Pisoni; Munther A Khamashta; Mimi Y Kim; Amit Saxena; Deborah Friedman; Carolina Llanos; Jean-Charles Piette; Jill P Buyon
Journal:  Circulation       Date:  2012-05-24       Impact factor: 29.690

3.  Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus.

Authors:  Amit Saxena; Peter M Izmirly; Sung Won Han; Paraskevi Briassouli; Tania L Rivera; Hua Zhong; Deborah M Friedman; Robert M Clancy; Jill P Buyon
Journal:  J Am Coll Cardiol       Date:  2015-08-25       Impact factor: 24.094

Review 4.  Neonatal Lupus: What We Have Learned and Current Approaches to Care.

Authors:  Marisa S Klein-Gitelman
Journal:  Curr Rheumatol Rep       Date:  2016-09       Impact factor: 4.592

5.  Maternal autoimmune disease and birth defects in the National Birth Defects Prevention Study.

Authors:  Meredith M Howley; Marilyn L Browne; Alissa R Van Zutphen; Sandra D Richardson; Sarah J Blossom; Cheryl S Broussard; Suzan L Carmichael; Charlotte M Druschel
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2016-11

6.  Complete Fetal Atrioventricular Block Associated with Maternal Autoinflammatory Diseases: Case Report and Literature Review.

Authors:  Ali Ulas Tugcu; Deniz Anuk Ince; Sertac Esin; Ozden Turan; Ilkay Erdogan; Ayse Ecevit
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

7.  Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study.

Authors:  Yan Luo; Lili Zhang; Yunyun Fei; Yiqun Li; Donglin Hao; Yi Liu; Yan Zhao
Journal:  Clin Rheumatol       Date:  2015-08-26       Impact factor: 2.980

Review 8.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

9.  Outcome of prenatally diagnosed isolated congenital complete atrioventricular block treated with transplacental betamethasone or ritodrine therapy.

Authors:  Taiyu Hayashi; Masahide Kaneko; Ki-Sung Kim; Yoshihiko Eryu; Takahiro Shindo; Takayoshi Isoda; Atsuko Murashima; Yushi Ito; Haruhiko Sago
Journal:  Pediatr Cardiol       Date:  2008-07-26       Impact factor: 1.655

10.  Prolonged Tpeak-Tend interval in anti-Ro52 antibody-positive connective tissue diseases.

Authors:  Ayse Nur Tufan; Saim Sag; Mustafa Ferhat Oksuz; Selime Ermurat; Belkis Nihan Coskun; Mustafa Gullulu; Ferah Budak; Ibrahim Baran; Yavuz Pehlivan; Ediz Dalkilic
Journal:  Rheumatol Int       Date:  2016-05-18       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.